Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of Bcl-2 expression and modulation of promyelocytic leukemia protein

Japanese Journal of Cancer Research

Volumn 91, Issue 6, 2000, Pages 604-611

  Zhang, Wen Jie ^a   Ohnishi, Kazunori ^a   Yoshida, Hitoshi ^a   Pan, Ling ^a   Maksumova, Lola ^a   Muratkhodjaev, Farkhad ^a   Luo, Jian Min ^a   Shigeno, Kazuyuki ^a   Fujisawa, Shinya ^a   Naito, Kensuke ^a   Nakamura, Satoki ^a   Shinjo, Kaori ^a   Takeshita, Akihiro ^a   Ohno, Ryuzo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcl 2; KRN5500; PML; Spicamycin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ANTINEOPLASTIC AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; RETINOIC ACID; SPICAMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DAUDI CELL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; LEUKEMIA CELL LINE; LYMPHOID CELL LINE; MULTIPLE MYELOMA; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 0033945247     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00988.x     Document Type: Article

References (29)

1. Hayakawa, Y., Nakagawa, M., Kawai, H., Tanabe, K., Nakayama, H. S. H., Shimazu, A., Seto, H. and Otake, N. Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells. J. Antibiot. (Tokyo), 36, 934-937 (1983).
2. Hayakawa, Y., Nakagawa, M., Kawai, H., Tanabe, K., Nakayama, H., Shimazu, A., Seto, H. and Otake, N. Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (M1) and human promyelocytic leukemia cells (HL-60). Agric. Biol. Chem., 49, 2685-2691 (1985).
3. Kamishohara, M., Kawai, H., Sakai, T., Isoe, T., Hasegawa, K., Mochizuki, J., Uchida, T., Kataoka, S., Yamaki, H., Tsuruo, T. and Otake, N. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncol. Res., 6, 383-390 (1994).
4. Kamishohara, M., Kawai, H., Sakai, T., Uchida, T., Tsuruo, T. and Otake, N. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer Chemother. Pharmacol., 38, 495-498 (1996).
5. Kawai, H. Protein synthesis inhibitor - antitumor activity and mode of action of KRN 5500. Cancer Chemother., 24, 1571-1577 (1997) (in Japanese).
6. Matsumura, Y., Kamiya, Y., Yamamoto, N., Ono, H., Shirao, K., Kondo, H., Tanigawara, Y., Tamura, T. and Shimada, Y. A phase I study of KRN5500 in patients with refractory solid tumors (stomach, colon, lung). Clin. Pharm., 18, 219a (1999).
7. Kataoka, T., Morishita, Y., Ogura, M., Morishima, Y., Towatari, M., Kato, Y., Inoue, H. and Saito, H. A novel human myeloid leukemia cell line, NKM-I, coexpressing granulocyte colony-stimulating factor receptors and macrophage colony-stimulating factor receptors. Cancer Res., 50, 7703-7709 (1990).
8. Ogura, M., Ueda, R., Takeo, T., Morishima, T., Hirabayashi, N. and Saito, H. Establishment and characterization of a novel human IgA, κ myeloma cell line (NOP-1) with CD4 antigen in vitro and vivo. Blood, 74, 81a (1990).
9. Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F. and Berger, R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood, 77, 1080-1086 (1991).
10. Dalton, W. T., Jr., Ahearn, M. J., McCredie, K. B., Freireich, E. J., Stass, S. A. and Trujillo, J. M. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood, 71, 242-247 (1988).
11. Klein, E., Klein, G., Nadkarni, J. S., Nadkarni, J. J., Wigzell, H. and Clifford, P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res., 28, 1300-1310 (1968).
12. Zhang, W.. Ohnishi, K., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Takeshita, K., Takeshita, A. and Ohno, R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia, 12, 1383-1391 (1998).
13. Steinkamp, J. A., Wilson, J. S., Saunders, G. C. and Stewart, C. C. Phagocytosis: flow cytometric quantitation with fluorescent microspheres. Science, 215, 64-66 (1982).
14. Lee, Y. S., Nishio, K., Ogasawara, H., Funayama, Y., Ohira, T. and Saijo, N. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Res., 55, 1075-1079 (1995).
15. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7, 547-553 (1995).
16. Peter, M. E. and Krammer, P. H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol., 10, 545-551 (1998).
17. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature, 387, 773-776 (1997).
18. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L. and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75, 241-251 (1993).
19. de The, H., Chomienne, C., Lanotte, M., Degos, L. and Dejean, A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature, 347, 558-561 (1990).
20. Grignani, F., Testa, U., Rogaia, D., Ferrucci, P. F., Samoggia, P., Pinto, A., Aldinucci, D., Gelmetti, V., Fagioli, M., Alcalay, M., Seeler, J., Grignani, F., Nicolitti, I., Peschle, C. and Pelicci, P. P. Effects on differentiation by the promyelocytic leukemia PML/RARA protein depend on the fusion of the PML protein dimerization and RARA DNA binding domains. EMBO J., 15, 4949-4958 (1996).
21. Yoshida, H., Kitamura, K., Tanaka, K., Omura, S., Miyazaki, T., Hachiya, T., Ohno, R. and Naoe, T. Accelerated degradation of PML-retinoic acid receptor α (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res., 56, 2945-2948 (1996).
22. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88, 1052-1061 (1996).
23. Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z. and de The, H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad Sci. USA, 94, 3978-3983 (1997).
24. Sternsdorf, T., Puccetti, E., Jensen, K., Hoelzer, D., Will, H., Ottmann, O. G. and Ruthardt, M. PIC-1/SUMO-1-modified PML-retinoic acid receptor a mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol. Cell. Biol., 19, 5170-5178 (1999).
25. Fagioli, M., Alcalay, M., Tomassoni, L., Ferrucci, P. F., Mencarelli, A., Riganelli, D., Grignani, F., Pozzan, T., Nicoletti, I., Grignani, F. and Pelicci, P. G. Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene, 16, 2905-2913 (1998).
26. Quignon, F., De Bels, F., Koken, M., Feunteun, J., Ameisen, J. C. and de The, H. PML induces a novel caspase-independent death process. Nat. Genet., 20, 259-265 (1998).
27. Wang, Z. G., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., Grosveld, F. and Pandolfi, P. P. Role of PML in cell growth and the retinoic acid pathway. Science, 279, 1547-1551 (1998).
28. Wang, Z. G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R. and Pandolfi, P. P. PML is essential for multiple apoptotic pathways. Nat. Genet., 20, 266-272 (1998).
29. Borden, K. L., CampbellDwyer, E. J. and Salvato, M. S. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. FEBS Lett., 418, 30-34 (1997).